Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.

Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: a meta-analysis

Abstract

Purpose This meta-analysis aimed to assess the efficacy and safety of once-weekly semaglutide among adults with overweight or obesity.Methods We searched multiple electronic databases for randomized controlled trials that compared once-weekly semaglutide versus placebo in adults with overweight or obesity. The primary outcomes were the percentage change and absolute change in body weight. Secondary outcomes included achievement of categorical weight loss targets (at least 5, 10, 15, or 20%), cardiometabolic risk profiles, and health-related quality of life.Results This meta-analysis included a total of four trials with 3447 patients. Once-weekly semaglutide was superior to placebo in terms of the percentage change and absolute change in body weight. Compared with placebo, once-weekly semaglutide also led to significant increases in the proportions of achievement of categorical weight reduction targets. Moreover, once-weekly semaglutide induced superior reductions in waist circumference and body-mass index compared with placebo. Furthermore, the effect on improving other cardiometabolic risk factors and health-related quality of life was more pronounced for once-weekly semaglutide relative to placebo.Conclusion Among adults with overweight or obesity, once-weekly semaglutide could result in clinically meaningful weight loss, which was a promising therapy for treating overweight or obesity.

Overview

Integrity signals

Registry

Crossref · 10.1007/s12020-021-02945-1

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 37 references

Research works printed but not linked: 1

  1. A.P. Courcoulas, N.J. Christian, S.H. Belle et al. Weight change and health outcomes at 3 years after bariatric surgery among individuals with severe obesity. JAMA 310(22), 2416–2425 (2013)

Cited by

See all 74

Metadata

Authors
Zhong, P., Zeng, H., Huang, M., Fu, W., & Chen, Z.
Affiliations
  • Guangzhou University of Chinese Medicine (CN)
  • Jinan University (CN)
  • Guangdong Provincial Hospital of Chinese Medicine (CN)
Corresponding author
  • Fu, Wenbin
  • Chen, Zhixia
Venue
Endocrine
Published
2022-01-04
Volume
75
Issue
3
Pages
718-724
ISSN
  • 0969-711X (ISSN-L)
  • 1355-008X
  • 1559-0100
OpenAlex
W4206202672
Cited by
74
References
37
Citations by year
2026: 8 · 2025: 19 · 2024: 15 · 2023: 18 · 2022: 14
FWCI
2.37
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Endocrine (publishedVersion)
  • PubMed (publishedVersion)
Funders
scientific research project of guangdong provincial administration of traditional chinese medicine (No. 2020KT1112)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Keywords
semaglutide, obesity, overweight, weight loss, GLP-1 receptor agonists, body weight, cardiometabolic risk, health-related quality of life, waist circumference, body mass index, drug safety
MeSH terms
Semaglutide, Adult, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Obesity, Quality of Life, Overweight

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: a meta-analysis. https://app.cochat.ai/papers/10.1007/s12020-021-02945-1
The paper
Zhong, P., Zeng, H., Huang, M., Fu, W., & Chen, Z. (2022). Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: a meta-analysis. Endocrine. https://doi.org/10.1007/s12020-021-02945-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.